hepat
e
viru
hev
caus
agent
hepat
e
human
member
genu
orthohepeviru
famili
hepevirida
hev
infect
common
caus
acut
hepat
also
take
chronic
cours
ribavirin
treatment
choic
patient
type
interferon
ifn
evalu
infect
transplant
patient
vivo
howev
effect
specif
treatment
hev
infect
current
avail
studi
evalu
natur
compound
silvestrol
isol
plant
aglaia
foveolata
known
specif
inhibit
deadbox
rna
helicas
stateoftheart
hev
experiment
model
system
silvestrol
block
hev
replic
differ
subgenom
replicon
dosedepend
manner
low
nanomolar
concentr
act
addit
ribavirin
rbv
addit
hev
full
length
replic
product
infecti
particl
reduc
presenc
silvestrol
pangenotyp
effect
compound
demonstr
primari
isol
four
differ
human
genotyp
hev
infect
experi
hepatocytelik
cell
deriv
human
embryon
induc
pluripot
stem
cell
vivo
hev
rna
level
rapidli
declin
fece
treat
mice
effect
observ
vehicl
treat
control
anim
conclus
silvestrol
could
identifi
pangenotyp
hev
replic
inhibitor
vitro
addit
effect
rbv
demonstr
high
potenc
vivo
compound
therefor
may
consid
futur
treatment
strategi
chronic
hepat
e
immunocompromis
patient
hepat
e
viru
hev
caus
agent
hepat
e
human
classifi
member
genu
orthohepeviru
within
hepevirida
famili
worldwid
hepat
e
lead
caus
acut
viral
hepat
approxim
million
peopl
infect
hev
caus
approx
million
case
acut
ill
lead
nearli
death
per
year
pathogen
substanti
impact
human
life
need
socioeconom
consid
wedemey
et
al
least
four
humanpathogen
hev
genotyp
exist
genotyp
sole
infect
human
mainli
present
develop
area
caus
waterborn
outbreak
pregnant
women
harbor
high
risk
fatal
outcom
hev
infect
mortal
rate
last
trimest
kamar
et
al
contrast
gt
zoonot
pathogen
main
reservoir
pig
wild
boar
deer
say
et
al
contact
anim
consumpt
contamin
meatproduct
major
risk
factor
acquir
hev
infect
latter
genotyp
respons
infect
industri
nation
hev
gt
infect
human
usual
selflimit
evolv
also
chronic
immunosuppress
individu
risk
develop
liver
cirrhosi
eventu
hepat
decompens
need
liver
transplant
behrendt
et
al
current
therapi
use
treat
hev
infect
includ
ribavirin
interferonalpha
sever
side
effect
contraind
pregnant
woman
furthermor
viru
isol
recent
identifi
possess
lower
ribavirin
sensit
lead
higher
treatment
failur
rate
debe
et
al
todt
et
al
todt
et
al
therefor
efficaci
safe
antivir
treatment
hev
urgent
need
screen
approach
novel
hev
inhibitor
identifi
natur
compound
silvestrol
silvestrol
structur
uniqu
cyclopenta
b
benzofuran
isol
plant
aglaia
foveolata
belong
famili
meliaca
kim
et
al
describ
highli
effici
nontox
specif
inhibitor
deadbox
rna
helicas
bordeleau
et
al
part
complex
drive
capdepend
translat
initi
eukaryot
silvera
et
al
studi
show
silvestrol
inhibit
replic
differ
hev
gt
dosedepend
manner
low
nanomolar
concentr
antihev
activ
observ
infect
experi
laboratori
primari
isol
human
liver
cell
vivo
use
human
mice
result
identifi
silvestrol
novel
natur
compound
block
hev
replic
could
therefor
part
antivir
strategi
treatment
hev
infect
silvestrol
receiv
medchem
express
monmouth
junction
nj
usa
ribavirin
rbv
receiv
sigma
aldrich
st
loui
mo
usa
compound
store
dilut
accord
manufactur
recommend
human
liver
cell
line
cultur
dulbecco
modifi
eagl
medium
dmem
invitrogen
karlsruh
germani
supplement
fc
ge
healthcar
streptomycin
iuml
penicillin
invitrogen
mm
lglutamin
nonessenti
amino
acid
invitrogen
dmem
complet
subclon
cultur
eagl
minimum
essenti
medium
mem
glutamin
invitrogen
ultralow
igg
fc
invitrogen
mm
lglutamin
gentamicin
mm
sodium
pyruv
nonessenti
amino
acid
invitrogen
cell
grown
rat
collagenco
serva
electrophoresi
gmbh
heidelberg
germani
cultur
plate
cell
kept
volvol
co
incub
plasmid
construct
contain
fulllength
hev
genom
clone
genbank
access
four
construct
harbor
subgenom
hev
sequenc
coupl
gaussia
luciferas
report
gene
use
gener
hev
vitro
transcript
previous
describ
drave
et
al
one
construct
deriv
strain
base
clone
psk
genbank
access
two
construct
base
genom
one
contain
polymeras
mutat
todt
et
al
gaussia
luciferas
coupl
construct
deriv
viru
genbank
access
kind
gift
laboratori
takaji
wakita
cap
construct
perform
use
cap
analog
promega
madison
wi
usa
hcv
subgenom
replicon
use
refer
construct
describ
anggakusuma
et
al
primari
isol
strain
viral
rna
copiesml
viral
rna
copiesml
fecal
suspens
infect
macaqu
supernat
cell
viral
rna
copiesml
kind
gift
suzann
u
emerson
emerson
et
al
primari
isol
strain
viral
rna
copiesml
strain
viral
rna
copiesml
fecal
suspens
infect
pig
kind
gift
xiangjin
meng
virginia
tech
feagin
et
al
esc
ipsc
differenti
hlc
previous
describ
wu
et
al
human
liver
chimer
mice
human
mice
gener
transplant
primari
human
hepatocyt
donor
corn
homozyg
upa
scid
mice
previous
describ
meuleman
et
al
human
mice
inocul
via
intrasplen
rout
filter
fecal
suspens
contain
iu
genotyp
hev
strain
gener
provid
dr
suzann
emerson
nih
usa
four
week
inocul
mice
treat
daili
intraperiton
dose
mgkg
silvestrol
formul
sigmaaldrich
vehicl
stool
sampl
collect
daili
basi
viral
rna
detect
quantifi
mous
stool
suspens
use
previous
describ
rtqpcr
say
et
al
dosedepend
inhibit
replic
plot
use
grahpad
prism
window
la
jolla
california
usa
wwwgraphpad
com
ic
ic
cc
calcul
use
fourparamet
loglogist
model
statist
signific
differ
mean
calcul
use
oneway
anova
follow
dunnett
multipl
comparison
test
indic
p
valu
consid
signific
ns
nonsignific
hev
viral
mrna
contain
highli
structur
need
translat
cellular
translat
machineri
order
promot
viral
protein
synthesi
silvestrol
specif
inhibitor
host
encod
rna
helicas
promot
capdepend
translat
initi
gingra
et
al
analys
effect
silvestrol
hev
first
transfect
human
hepatoma
cell
line
differ
hev
subgenom
replicon
part
replac
gaussia
luciferas
report
gene
includ
hev
gt
construct
shukla
et
al
variant
thereof
increas
replic
fit
debe
et
al
todt
et
al
wild
boar
isol
shiota
et
al
gt
strain
harbor
insert
like
strain
shukla
et
al
depict
fig
incub
silvestrol
h
result
dosedepend
inhibit
hev
replic
inhibitori
concentr
ic
nm
differ
hev
construct
fig
tabl
known
hev
inhibitor
rbv
higher
concentr
rang
need
inhibit
hev
replic
ic
fig
tabl
replicon
ic
observ
rbv
fig
tabl
hcv
employ
refer
viru
less
suscept
silvestrol
translat
initi
occur
capindepend
via
intern
ribosom
entri
site
ire
fig
cell
viabil
determin
mtt
assay
enzymat
activ
start
decreas
higher
concentr
reach
cytotox
concentr
cc
line
report
data
cencic
et
al
biedenkopf
et
al
fig
addit
determin
viabl
cell
silvestrol
treatment
demonstr
signific
reduct
fig
treatment
silvestrol
h
result
even
lower
ic
valu
exampl
nm
strain
cc
valu
nm
fig
tabl
result
select
index
longer
incub
time
presenc
silvestrol
result
decreas
cell
viabil
data
shown
overal
rbv
cell
viabil
profil
h
similar
comparison
shorter
treatment
fig
next
inhibitori
effect
silvestrol
evalu
fulllength
clone
cell
visual
hev
antigen
express
perform
indirect
immunofluoresc
stain
structur
capsid
protein
depict
fig
posit
cell
highli
reduc
high
dose
nm
silvestrol
rbvtreat
cell
fig
summari
natur
compound
silvestrol
demonstr
antivir
activ
differ
hev
gt
nontox
concentr
replic
depict
dosedepend
inhibit
replic
transfect
hev
replicon
silvestrol
ribavirin
continu
xax
treatment
h
h
c
reduct
replic
determin
via
report
luciferas
readout
normal
respect
dmso
treat
control
yax
three
genotyp
replicon
one
genotyp
replicon
employ
compar
control
replicon
base
hepat
c
viru
solid
line
see
legend
color
code
cell
viabil
monitor
via
mtt
assay
shown
dot
line
addit
antiprolif
properti
silvestrol
medium
concentr
nm
high
concentr
nm
assess
via
visual
cell
count
trypan
blue
stain
compar
ribavirin
treat
untreat
cell
b
ns
nonsignific
e
immunofluoresc
stain
transfect
cell
treat
silvestrol
low
concentr
nm
medium
concentr
nm
ribavirin
dmso
h
transfect
h
next
evalu
antivir
effect
silvestrol
hev
infect
experi
use
cell
culturederiv
infecti
hev
hev
cc
base
isol
dao
thi
et
al
cell
patientderiv
hev
gt
pluripot
stem
cellderiv
hepatocytelik
cell
hlc
wu
et
al
first
evalu
antivir
activ
silvestrol
replicon
cell
line
observ
shift
doserespons
curv
comparison
suppl
fig
case
hev
cc
infect
assay
treatment
setup
silvestrol
concentr
nm
h
h
day
day
time
interv
carri
fig
experiment
read
determin
infecti
particl
product
focu
form
unit
ffuml
cell
lysat
first
round
infect
fig
inhibit
hev
replic
promin
nm
nm
treatment
late
time
point
fig
rbv
treatment
serv
control
demonstr
inhibitori
effect
late
treatment
combinatori
arm
fig
silvestrol
incub
cell
viabil
reduc
fig
next
patientderiv
hev
gt
use
infect
hlc
treat
h
postinfect
silvestrol
h
fig
inhibitori
effect
natur
compound
nonadapt
hev
isol
noncarcinoma
cell
line
confirm
major
human
pathogen
genotyp
fig
without
cytotox
fig
conclus
infect
hepatoma
hlc
cell
differ
hev
isol
reduc
treatment
silvestrol
recent
sever
studi
demonstr
human
liver
chimer
mice
infect
hev
use
tool
studi
chronic
hev
infect
antivir
drug
vivo
allweiss
dandri
van
de
gard
et
al
say
et
al
evalu
antivir
effect
silvestrol
vivo
chose
base
previou
work
hwang
et
al
saradhi
et
al
silvestrol
dose
mgkg
administ
intraperiton
hev
strain
infect
mice
two
mice
treat
daili
basi
ten
day
six
day
respect
two
addit
serv
control
treat
vehicl
depict
fig
first
day
treatment
rapid
declin
hev
rna
observ
fece
treat
mice
effect
observ
vehicl
treat
control
anim
fig
chang
bodi
weight
either
anim
note
monitor
period
success
engraft
human
hepatocyt
mous
liver
ensur
assess
human
serum
albumin
level
blood
sampl
drawn
treatment
supp
fig
result
implic
strong
antivir
effect
silvestrol
hev
anim
model
system
rbv
treatment
choic
offlabel
medic
chronic
infect
patient
next
perform
combinatori
treatment
silvestrol
rbv
follow
electropor
cell
rna
genom
harbor
gaussia
luciferas
report
gene
cell
grown
presenc
variou
dose
silvestrol
rbv
combin
luciferas
assay
readout
perform
h
h
treatment
character
interact
combin
drug
compound
mix
variou
molar
ratio
match
equipot
concentr
silvestrol
rbv
analyz
use
compusyn
softwar
fig
accord
method
choutalalay
chou
talalay
combin
indic
ci
calcul
ci
ic
ic
ic
h
treatment
rang
h
treatment
indic
rang
indic
addit
antivir
effect
combin
silvestrol
ribavirin
also
reflect
posit
experiment
data
point
close
proxim
line
addit
isobologram
fig
c
fraction
addit
data
analyz
accord
bliss
independ
model
prichard
shipman
threedimension
differenti
surfac
plot
depict
fig
h
treatment
fig
h
treatment
observ
minim
elev
plane
h
low
silvestrol
concentr
minor
decreas
plane
h
low
silvestrol
concentr
taken
togeth
result
suggest
minim
chang
mode
addit
combin
silvestrol
rbv
differ
ratio
employ
assay
setup
drug
show
addit
effect
inhibit
hev
replicon
replic
cellular
viral
mrna
reli
capdepend
mrna
translat
canon
mechan
initi
commenc
recognit
end
cap
structur
complex
form
deadbox
helicas
scaffold
protein
todt
et
al
antivir
research
cap
recognit
factor
sonenberg
hinnebusch
natur
compound
silvestrol
identifi
studi
novel
hev
inhibitor
report
abil
modul
translat
prevent
ribosom
load
onto
mrna
templat
target
eukaryot
initi
factor
bordeleau
et
al
cencic
et
al
interestingli
zhou
et
al
previous
investig
role
complex
hev
replic
found
line
activ
silvestrol
describ
effici
replic
hev
requir
mrna
translat
machineri
zhou
et
al
program
cell
death
protein
neg
regulatori
factor
complex
exert
antihev
activ
illustr
requir
support
hev
replic
zhou
et
al
therefor
molecul
like
intracellular
virus
obtain
freezethaw
lysi
use
infect
well
plate
focu
form
unit
ffu
count
b
amount
infecti
viral
particl
produc
treatment
differ
dose
silvestrol
sil
ribavirin
rbv
normal
dmso
treat
control
c
cell
viabil
monitor
via
mtt
assay
normal
dmso
control
reduct
hev
rna
copi
number
hlc
infect
primari
isol
hev
genotyp
hev
cc
treatment
nm
silvestrol
h
pi
protocol
normal
dmso
treat
control
e
cell
viabil
monitor
via
wst
assay
normal
dmso
control
silvestrol
target
mrna
translat
host
factor
open
new
perspect
futur
antivir
strategi
hosttarget
agent
hta
like
exhibit
higher
barrier
viral
resist
develop
compar
specif
viral
target
antivir
activ
silvestrol
describ
ebola
viru
replic
biedenkopf
et
al
inhibit
viral
propag
treatment
silvestrol
occur
rapidli
effect
cellular
function
ic
lower
nm
observ
biedenkopf
et
al
recent
potent
antivir
activ
also
report
coronavirus
includ
merscov
picornavirus
reveal
broadspectrum
activ
muller
et
al
hev
observ
also
antivir
activ
low
nanomolar
concentr
human
gt
swine
isol
well
viral
variant
identifi
hevinfect
patient
confer
enhanc
replic
fit
fig
debe
et
al
todt
et
al
hcv
capindepend
replic
control
less
suscept
silvestrol
howev
also
fig
antivir
effect
silvestrol
hepat
e
viru
hev
infect
human
liver
chimer
mice
hev
genotyp
inocul
mice
treat
daili
intraperiton
dose
mgkg
silvestrol
ten
hexagon
diamond
six
day
circl
squar
red
line
two
mice
vehicl
triangl
black
line
two
mice
stool
sampl
collect
daili
basi
viral
rna
detect
quantifi
via
rtqpcr
b
bodi
weight
anim
monitor
time
assay
color
shape
accord
iresdepend
translat
machineri
might
requir
help
addit
translat
initi
factor
infect
host
cell
thompson
antihev
activ
silvestrol
subsequ
confirm
viral
infect
assay
determin
product
infecti
particl
compound
incub
howev
overal
antivir
activ
silvestrol
reduc
assay
compar
replicon
system
cell
higher
concentr
drug
need
suppl
fig
addit
pangenotyp
activ
silvestrol
observ
use
primari
isol
four
differ
gt
hlc
deriv
human
embryon
induc
pluripot
stem
cell
fig
hlc
offer
improv
physiolog
relev
traceabl
system
studi
replic
antivir
respons
primari
hev
isol
wu
et
al
previous
silvestrol
mainli
character
antitumor
model
chronic
lymphocyt
leukemia
acut
lymphocyt
leukemia
mantl
cell
lymphoma
also
hepatocellular
carcinoma
cencic
et
al
luca
et
al
alinari
et
al
kogur
et
al
noteworthi
clinic
effort
underway
target
specif
compon
translat
apparatu
uniqu
mrna
translat
element
cancer
therapeut
silvera
et
al
bhat
et
al
base
vivo
studi
inhibitori
effect
silvestrol
addit
investig
human
mice
infect
hev
show
reduct
viral
load
first
day
treatment
fig
proof
concept
valid
vivo
guid
silvestrolbas
antivir
strategi
could
also
involv
combin
treatment
rbv
combin
two
drug
distinct
mechan
action
involv
advantag
possibl
synergist
antivir
effect
decreas
danger
emerg
resist
except
import
therapeut
intervent
chronic
hev
infect
immunosuppress
patient
todt
et
al
addit
synergist
antivir
effect
impli
possibl
reduc
dose
dose
frequenc
two
compound
even
minim
potenti
toxic
advers
effect
employ
two
model
analys
interact
silvestrol
rbv
combin
accord
recommend
zhao
colleagu
zhao
et
al
combin
indic
isobologram
calcul
base
choutalalay
method
well
threedimension
surfac
plot
determin
use
bliss
independ
model
suggest
addit
antivir
effect
drug
fig
also
slight
deviat
line
addit
planar
plot
observ
extrem
dose
antivir
low
high
effect
level
care
titrat
compound
vitro
vivo
recommend
identifi
optim
ratio
drug
increas
antivir
activ
along
reduc
danger
emerg
resist
improv
toler
clinic
set
summari
natur
compound
silvestrol
specif
target
host
factor
capdepend
translat
initi
could
identifi
novel
pangenotyp
antihev
agent
viral
replic
inhibit
silvestrol
dosedepend
manner
low
nanomolar
concentr
differ
hev
experiment
model
system
includ
hev
primari
isol
hevinfect
human
mice
thu
silvestrol
may
consid
futur
treatment
strategi
chronic
hepat
e
immunocompromis
patient
author
declar
conflict
interest
